{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:00:19Z","timestamp":1794304819220,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Re-Vana Therapeutics Ltd, Belfast, UK"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jpba.2019.05.038","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T23:59:59Z","timestamp":1558483199000},"page":"145-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations"],"prefix":"10.1016","volume":"174","author":[{"given":"Feras","family":"Jirjees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sheshala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-2082","authenticated-orcid":false,"given":"Raghu Raj Singh","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2019.05.038_bib0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jpba.2019.05.038_bib0010","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/ijms18081786","article-title":"A review of anti-angiogenic targets for monoclonal antibody cancer therapy","volume":"18","author":"Kong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2019.05.038_bib0015","series-title":"Avastin\u00ae (bevacizumab) Injection, for Intraveous Use","author":"U.S. Food","year":"2017"},{"key":"10.1016\/j.jpba.2019.05.038_bib0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","article-title":"FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.jpba.2019.05.038_bib0025","series-title":"FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer","author":"U.S. Food","year":"2018"},{"key":"10.1016\/j.jpba.2019.05.038_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: bevacizumab (Avastin\u00ae) Plus Carboplatin and Paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.jpba.2019.05.038_bib0035","first-page":"65","article-title":"The off-label use of medication: the latest on the Avastin - Lucentis debacle","volume":"32","author":"Jansen","year":"2013","journal-title":"Med. Law"},{"key":"10.1016\/j.jpba.2019.05.038_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2019.05.038_bib0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.addr.2006.03.011","article-title":"Formulation and delivery issues for monoclonal antibody therapeutics","volume":"58","author":"Daugherty","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpba.2019.05.038_bib0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jpba.2019.05.038_bib0055","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of Avastin\u00ae from polysaccharides cross-linked hydrogels for ocular drug delivery","volume":"60","author":"Xu","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jpba.2019.05.038_bib0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.jpba.2019.05.038_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2019.05.038_bib0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijbiomac.2018.05.142","article-title":"Validated reverse phase HPLC diode array method for the quantification of intact bevacizumab, infliximab and trastuzumab for long-term stability study","volume":"116","author":"Mart\u00ednez-Ortega","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jpba.2019.05.038_bib0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jpba.2017.05.015","article-title":"Development and validation of a rapid reversed-phase HPLC method for the quantification of monoclonal antibody bevacizumab from polyester-based nanoparticles","volume":"142","author":"Sousa","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2019.05.038_bib0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.aca.2016.02.029","article-title":"Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification","volume":"916","author":"Todoroki","year":"2016","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2019.05.038_bib0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.15583\/jpchrom.2017.014","article-title":"High sensitivity and precision high-temperature reversed-phase LC analysis of bevacizumab for intact bioanalysis of therapeutic monoclonal antibodies","volume":"39","author":"Yamada","year":"2018","journal-title":"Chromatography"},{"key":"10.1016\/j.jpba.2019.05.038_bib0090","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2017.10.042","article-title":"A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC\u2013MS\/MS in human plasma comparing two internal standard calibration approaches","volume":"1070","author":"Legeron","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2019.05.038_bib0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dmpk.2015.11.004","article-title":"Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis","volume":"31","author":"Iwamoto","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2019.05.038_bib0100","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1080\/10826076.2012.743724","article-title":"Size-exclusion chromatography for the analysis of protein biotherapeutics and their aggregates","volume":"35","author":"Hong","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/j.jpba.2019.05.038_bib0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0958-6946(01)00032-2","article-title":"Reversed phase and size exclusion chromatography of milk protein hydrolysates: relation between elution from reversed phase column and apparent molecular weight distribution","volume":"11","author":"van der Ven","year":"2001","journal-title":"Int. Dairy J."},{"key":"10.1016\/j.jpba.2019.05.038_bib0110","first-page":"1027","article-title":"Establishment of an HPLC quantitative method for bevacizumab","volume":"35","author":"Zou","year":"2015","journal-title":"Chinese J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2019.05.038_bib0115","series-title":"Validation of Analytical Procedures: Text and Methodology Q2(R1)","author":"International Conference on Harmonization","year":"2005"},{"key":"10.1016\/j.jpba.2019.05.038_bib0120","series-title":"Bioanalytical Method Validation - Guidance for Industry","author":"U.S. Food","year":"2018"},{"key":"10.1016\/j.jpba.2019.05.038_bib0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11095-017-2298-9","article-title":"Synthesis and characterisation of photocrosslinked poly(ethylene glycol) diacrylate implants for sustained ocular drug delivery","volume":"35","author":"McAvoy","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2019.05.038_bib0130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/HAB-2011-0244","article-title":"Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (Avastin\u2122) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies","volume":"20","author":"Kaja","year":"2011","journal-title":"Hum. Antibodies"},{"key":"10.1016\/j.jpba.2019.05.038_bib0135","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s11095-016-1940-2","article-title":"Hydrodynamic radii of ranibizumab, aflibercept and bevacizumab measured by time-resolved phosphorescence anisotropy","volume":"33","author":"Hirvonen","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2019.05.038_bib0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11095-018-2368-7","article-title":"Formulation stabilization and disaggregation of bevacizumab, ranibizumab and aflibercept in dilute solutions","volume":"35","author":"Giannos","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2019.05.038_bib0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pharma.2009.05.008","article-title":"Mechanically-induced aggregation of the monoclonal antibody cetuximab","volume":"67","author":"Lahlou","year":"2009","journal-title":"Ann. Pharm. Fran\u00e7aises."},{"key":"10.1016\/j.jpba.2019.05.038_bib0150","series-title":"Center for Drug Evaluation and Research - Reviewer Guidance on Validation of Chromatographic Methods","year":"1994"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851930072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851930072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T16:54:57Z","timestamp":1564160097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851930072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"alternative-id":["S073170851930072X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.038","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2019.05.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}